Valeant considering sale of eye-surgery assets — Carl Zeiss interest rumored

Bloomberg reports Valeant Pharmaceuticals is considering selling its Bausch & Lomb surgical products to Carl Zeiss Meditec.

Here's what you should know:

1. Analysts believe Bausch & Lomb is worth $2 billion.

2. Anonymous sources told Bloomberg talks are ongoing with an agreement "still weeks away."

3. Valeant could consider other bidders.

4. Valeant has $28.9 billion in debt. CEO Joe Papa is working to stabilize the company after it suffered from government pricing probes coupled with poor sales.

More articles on improving health:
ASCA Healthcare Asset Network to create online shopping portal: 4 features
10 states where the most people delay necessary medical care
20 latest notes on hourly, annual wages for ASC nurses, tech & administrative staff

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.


Featured Webinars

Featured Whitepapers